About Atossa Therapeutics
Atossa Therapeutics is a company based in Seattle (United States) founded in 2009 by Steven Quay.. Atossa Therapeutics has raised $13.52 million across 7 funding rounds from investors including Aspire Capital. The company has 15 employees as of December 31, 2024. Atossa Therapeutics offers products and services including (Z)-endoxifen and EVANGELINE Study Program. Atossa Therapeutics operates in a competitive market with competitors including Daré Bioscience, Olema Oncology, Puma Biotechnology, Ambagon and Minerva Biotechnologies, among others.
- Headquarter Seattle, United States
- Employees 15 as on 31 Dec, 2024
- Founders Steven Quay
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Atossa Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-25.5 M15.25as on Dec 31, 2024
-
EBITDA
$-27.6 M11.96as on Dec 31, 2024
-
Total Equity Funding
$13.52 M (USD)
in 7 rounds
-
Latest Funding Round
$21 M (USD), Post-IPO
Jan 29, 2021
- Investors
-
Employee Count
15
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Atossa Therapeutics
Atossa Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ATOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Atossa Therapeutics
Atossa Therapeutics offers a comprehensive portfolio of products and services, including (Z)-endoxifen and EVANGELINE Study Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for breast cancer prevention and treatment in clinical trials.
Phase 2 trial for ER+ breast cancer neoadjuvant treatment.
Funding Insights of Atossa Therapeutics
Atossa Therapeutics has successfully raised a total of $13.52M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $21.0M
-
First Round
First Round
(21 Jan 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Post-IPO - Atossa Therapeutics | Valuation |
investors |
|
| Apr, 2013 | Amount | Post-IPO - Atossa Therapeutics | Valuation |
investors |
|
| Mar, 2013 | Amount | Post-IPO - Atossa Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Atossa Therapeutics
Atossa Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Aspire Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Atossa Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Atossa Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Atossa Therapeutics Comparisons
Competitors of Atossa Therapeutics
Atossa Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Olema Oncology, Puma Biotechnology, Ambagon and Minerva Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
Drug therapeutics for breast cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Tyrosine kinase inhibitors for breast cancer are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapy and antibodies are developed to treat cancer.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Atossa Therapeutics
Frequently Asked Questions about Atossa Therapeutics
When was Atossa Therapeutics founded?
Atossa Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Where is Atossa Therapeutics located?
Atossa Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Atossa Therapeutics?
Steven Quay is the current CEO of Atossa Therapeutics. They have also founded this company.
Is Atossa Therapeutics a funded company?
Atossa Therapeutics is a funded company, having raised a total of $13.52M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $1M, raised on Jan 21, 2010.
How many employees does Atossa Therapeutics have?
As of Dec 31, 2024, the latest employee count at Atossa Therapeutics is 15.
What does Atossa Therapeutics do?
Founded in 2009 and based in Seattle, United States, focus is placed on biotechnology for oncology. Endoxifen is developed in topical and oral forms to address breast cancer prevention and treatment. A nasal spray and additional therapeutic are pursued for COVID-19 management. Operations center on drug development within the pharmaceutical sector.
Who are the top competitors of Atossa Therapeutics?
Atossa Therapeutics's top competitors include Daré Bioscience, Puma Biotechnology and Minerva Biotechnologies.
What products or services does Atossa Therapeutics offer?
Atossa Therapeutics offers (Z)-endoxifen and EVANGELINE Study Program.
Is Atossa Therapeutics publicly traded?
Yes, Atossa Therapeutics is publicly traded on NASDAQ under the ticker symbol ATOS.
Who are Atossa Therapeutics's investors?
Atossa Therapeutics has 1 investor. Key investors include Aspire Capital.
What is Atossa Therapeutics's ticker symbol?
The ticker symbol of Atossa Therapeutics is ATOS on NASDAQ.